U.S. to review drug intended for one race.
Saul
Stephanie
S
D001741:Black or African American / Q000235:genetics*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000592:standards; D017277:Drug Approval; D004338:Drug Combinations; D004345:Drug Industry / Q000191:economics; D006333:Heart Failure / Q000188:drug therapy* / Q000208:ethnology* / Q000235:genetics; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use*; D007548:Isosorbide Dinitrate / Q000627:therapeutic use*; D008389:Marketing of Health Services; D010597:Pharmacogenetics; D044469:Racial Groups / Q000235:genetics; D014481:United States; D014486:United States Food and Drug Administration
D002317:Cardiovascular Agents; D004338:Drug Combinations; C431665:isosorbide-hydralazine combination; D006830:Hydralazine; D007548:Isosorbide Dinitrate